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Abstract 32 
Background: The identification of early biomarkers of psychotic experiences (PEs) is of 33 
interest as early diagnosis and treatment of those at risk of future disorder is associated with 34 
improved outcomes. The current study investigated early lipidomic and coagulation pathway 35 
protein signatures of later PEs in subjects from the Avon Longitudinal Study of Parents and 36 
Children cohort.  37 
Methods: Plasma of 115 children (age 12) who were first identified as experiencing PEs at 38 
age 18 (48 cases and 67 controls) were assessed through integrated and targeted lipidomics 39 
and semi-targeted proteomics approaches. We assessed the lipids, LPCs (n=11) and PCs 40 
(n=61), and the protein members of the coagulation pathway (n=22) and integrated this data 41 
with complement pathway protein data already available on these subjects.   42 
Results: Twelve PCs, four LPCs and the coagulation protein plasminogen were altered 43 
between the control and PE group after correction for multiple comparisons. Lipidomic and 44 
proteomic datasets were integrated into a multivariate network displaying a strong 45 
relationship between most lipids that were significantly associated to PEs and plasminogen. 46 
Finally, an unsupervised clustering approach identified four different clusters with one of the 47 
clusters presenting the highest ratio cases:controls (P < 0.01) and associated with a higher 48 
concentration of smaller LDL cholesterol particles.  49 
Conclusions: Our findings indicate that the lipidome and proteome of subjects who report 50 
PEs at age 18 is already altered at age 12 indicating that metabolic dysregulation may 51 
contribute to an early vulnerability to PEs and suggesting cross-talk between these LPCs, PCs 52 
and coagulation and complement proteins.   53 
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INTRODUCTION 54 
The early identification and treatment of subjects with psychiatric disorders, both psychotic 55 
and affective, significantly improves their clinical outcome (1). Consequently, over the last 56 
decade, there has been a shift in research focus to a high-risk paradigm for individuals at 57 
increased risk for later psychotic disorder (2–4). Research over the past 15 years has revealed 58 
that 8-17% of children and adolescents (5) and 7% of adults (6) in the general population 59 
report psychotic experiences. It is known that these individuals who report subclinical 60 
symptoms in early life are at increased risk of psychotic disorder (7, 8) as well as other 61 
disorders (9, 10). 62 
The identification of a biological signature of psychotic illnesses can provide insights into 63 
pathophysiological basis of the disorders (11, 12) and also has the potential to be used as a 64 
part of biomarker signature for early detection and diagnosis (13). Recent research on 65 
schizophrenia and related psychoses have highlighted a number of metabolic perturbations 66 
such as glucoregulatory processes (14, 15), lipid metabolism (16–18), mitochondrial function 67 
(19), proline (13) and tryptophan metabolism (20) with the most consistent findings involving 68 
pathways common to fatty acids and the pro-oxidant/antioxidant balance (21–23). A recent 69 
systematic review of metabolite biomarkers for schizophrenia by Davison and colleagues 70 
revealed that although definite consistencies have been described in the literature, none of the 71 
potential biomarkers have been validated reproducibly in large cohorts (24). Essential 72 
polyunsaturated fatty acids (EPUFAs), lipid-peroxidation metabolites, phosphatidylcholines 73 
(PCs) and lysophosphatidylcholines (LPCs), glutamate, 3-methoxy-4-hydroxyphenylglycol 74 
and vitamin E emerged from this review as potential biomarkers (24), emphasizing the 75 
hypotheses of  oxidative stress and inflammation (25), and membrane phospholipid 76 
alterations (26). While these studies have contributed to our understanding of the disease 77 
mechanisms, they generally focus on the adult population which have already transitioned to 78 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
5 
 
psychosis, with a majority being medicated. They are, therefore, limited in terms of 79 
identifying early molecular signatures of the disease.  80 
In order to address this issue, we recently applied broad metabolomics, lipidomics and 81 
shotgun and semi-targeted proteomics approaches to plasma samples from children at the age 82 
of 12 years that were reported to develop PD at the age of 18, from the ALSPAC cohort (27). 83 
We observed increased PCs and LPCs, and complement and coagulation proteins among 84 
these subjects during childhood (22, 23). These findings provided intriguing support for the 85 
view that psychosis is associated with a broad range of inflammatory (23, 28), gluco-86 
regulatory (29) and lipid dysregulation (22) from early childhood. The interrelationship 87 
between these early lipid and proteins changes has not yet been investigated. In the current 88 
investigation, we have extended our previous work by testing the hypothesis that altered 89 
LPCs and PCs and the family of coagulation proteins are associated not just with outcomes of 90 
PD, but with the milder phenotype of PEs. Specifically, lipidomic and semi-targeted 91 
proteomic approaches were employed to semi-target PCs and LPCs and coagulation proteins 92 
at the age of 12 among apparently well subjects who go on to develop PEs at the age of 18 in 93 
the ALSPAC cohort. This data was then integrated with other complement protein data 94 
available of the same subjects in order to assess the broader functional relationships between 95 
these proteins and lipids at age 12 among those who later report PEs at age 18. 96 
 97 
MATERIALS AND METHODS 98 
Study Cohort 99 
The study comprised of subjects from the cohort of the Avon Longitudinal Study of Parents 100 
and Children (ALSPAC). The ALSPAC cohort is a prospective general population cohort 101 
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that includes 14 062 live births from southwest England (30, 31). Written informed consent 102 
was acquired prior to taking the plasma samples. Ethical approval for the study was obtained 103 
from the ALSPAC Ethics and Law Committee and the Local Research Ethics Committees 104 
(RCSI REC 1240). Please note that the study website contains details of all the data that is 105 
available through a fully searchable data dictionary 106 
(http://www.bristol.ac.uk/alspac/researchers/our-data/). 107 
Measures of psychotic experiences (PE) and co-morbid depression 108 
PEs were identified at 12 and 18 years of age through the face-to-face, semi-structured 109 
Psychosis-Like Symptom (PLIKS) interview (27), conducted by trained psychology 110 
graduates in assessment clinics, and were coded according to the definitions and rating rules 111 
for the Schedules for Clinical Assessment in Neuropsychiatry, Version 2.0 (32). Interviewers 112 
rated PEs as not present, suspected or definitely psychotic. Patients were also assessed for the 113 
presence of depressive disorder according the ratings on the CIS-R whereby CIS-R scores >7 114 
are defined as fulfilling criteria for depression (28).  115 
Study Design 116 
We undertook a nested case-control study of the ALSPAC cohort and chose to assess all 117 
available plasma samples from age 12 children with outcomes of definite PEs at age 18 but 118 
who did not have PD (27). Available plasma samples from controls of age-matched 119 
individuals were then randomly selected. The present study consisted of a hypothesis-driven 120 
lipidomic and proteomic analysis of samples from 48 children without suspected or definite 121 
PEs at the age 12 but with definite PE at age 18 (n=48). Control samples (n=67) without 122 
suspected or definite PEs at the ages of 12 and 18, were selected (see Table 1). 123 
Socioeconomic status and presence of depression according to CIS-R scores were also tested. 124 
Plasma sampling 125 
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Non-fasting blood samples were collected from the participants into heparin Sarstedt S-126 
Monovette® tubes. Once collected samples were stored on ice for a maximum of 90 minutes 127 
until processed. Post centrifugation, the samples were stored at -80˚C until further analyses. 128 
Lipidomic analysis and data pre-processing 129 
Sample processing, data acquisition and quantification of lipids were performed as previously 130 
described (22). Lipidomic analysis was performed using an ultra-high-performance liquid 131 
chromatography quadrupole time-of-flight mass spectrometry (UHPLC-Q-TOF-MS) system 132 
(Agilent Technologies, USA).  133 
Lipidomic data were firstly processed using MZmine 2 (33), then normalized by lipid-class 134 
specific internal standards, and quantified using the inverse-weighted linear model (see 135 
Supplementary Methods). Analysis of lipidomics data was focused on detected PCs (n=61) 136 
and LPCs (n=11) based on our previous findings (22). 137 
Proteomic analysis and data pre-processing 138 
Sample analysis and data acquisition proteins were performed in the same individuals as 139 
examined in the current lipidomic analysis and using methods as previously described (23). 140 
To improve the dynamic range for proteomic analysis, 40µl of plasma from each case in all 141 
samples was immunodepleted of the 14 most abundant proteins (34) (see Supplementary 142 
Methods).  143 
Protein digestion and peptide purification was performed as previously described (35), and is 144 
further detailed in Supplementary Methods. We used the semi-targeted approach of Data 145 
Independent Acquisition (DIA) to specifically target the 22 members of the coagulation 146 
pathway (see Supplementary Table 1). For DIA analysis, 5µl of each sample was injected 147 
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into the Thermo Scientific Q-Exactive, connected to a Dionex Ultimate 3000 (RSLCnano) 148 
chromatography system, and data was acquired in DIA mode (see Supplementary Methods).  149 
Statistical analysis 150 
To assess differences of demographic data among groups, Pearson Chi square test and 151 
independent Student’s t-test were used on categorical and continuous variables, respectively.  152 
- Early PE signatures at age 12 153 
Principal component analysis (PCA) was used on the log-transformed, mean-centered and 154 
scaled to unit-variance lipidomics dataset to acquire an overview of the data. For supervised 155 
data analysis, uni- and multivariate approaches were performed.  156 
For univariate analysis, the Mann-Whitney U test was applied to the untransformed dataset in 157 
order to examine changes of lipids and proteins as related to PE. Benjamini-Hochberg false 158 
discovery rate (FDR) was applied in order to account for multiple comparisons.  159 
Multivariate modelling of PE was performed on the log-transformed data using a Partial 160 
Least Squares Discriminant Analysis (PLS-DA) of lipidomic profiles with the KODAMA R 161 
package v 1.4 (36). Modelling was performed in a repeated double cross-validation 162 
framework (37). The goodness of fit and prediction parameters were defined using a standard 163 
description reported elsewhere (38). The features were ranked in ascending order based on 164 
the absolute loading scores (termed as loading rank) (39). Model performance was further 165 
assessed through permutation test (R2), considering a statistical significance at P < 0.05. 166 
- Lipidomics and proteomics integration 167 
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Regularized canonical correlation analysis (rCCA) was performed on all individuals as an 168 
integrative multivariate approach to assess correlations between both lipidomics and 169 
proteomics data using the mixOmics R package v 5.2.0 (40).  170 
The method allows the study of the relationship of two multivariate datasets, for instance the 171 
relationship between specific lipids and proteins within the same individuals (41). 172 
Quantitative data, derived from DIA analysis, on the broad family of complement pathway 173 
proteins was also available on these same subjects (42) and this data was available for 174 
integrative analysis. Regularization parameters were estimated by means of a “leave one out” 175 
cross validation. Once the rCCA was acquired, the corresponding clustered heat maps, 176 
termed as Clustered Image Maps (cim), and the integrative network were acquired (43). Data 177 
was then exported to Gephi 0.9.2 and the layout algorithm Yifan Hu was used to allow the 178 
biological interpretation (44, 45). The network graph describes connections between lipids 179 
and proteins based on a similarity score > 0.3 (45). To evaluate obtained multivariate 180 
correlations, a further Spearman correlation analysis was implemented for each variable 181 
individually, considering the significant correlation at a P-value of < 0.05.  182 
- Identification of metabolic phenotypes 183 
The unsupervised algorithm based on the knowledge discovery by accuracy maximization 184 
(KODAMA) (46) was used to identify the underlying patterns representative of different 185 
metabolic phenotypes across all individuals. This learning algorithm allows an unsupervised 186 
clustering of individuals from noisy high-dimensional datasets (36). Partition around medoids 187 
(PAM) method (47) along with a silhouette algorithm (48) was carried out on KODAMA 188 
scores to identify the optimal distribution of clusters (49). Further descriptions of this method 189 
are shown elsewhere (36, 49). The demographic data and cholesterol profile were then tested 190 
among the identified clusters using the K-test. This method predicts an independent variable 191 
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using the variance in the KODAMA scores by means of permutation testing (49, 50). Thus, 192 
causality of phenotyping was explored by other variables (49) such as the cholesterol profile 193 
and demographics. Data on cholesterol profile including cholesterol esters and lipoprotein 194 
particle data of selected individuals at age 7 were measured  and reported elsewhere (51) 195 
(30). Statistical significance was considered at an FDR-corrected P-value of < 0.05.  196 
All statistical analyses were performed in the statistical programming environment R v. 3.3.1 197 
(52). Data used for this submission will be made available on request to the ALSPAC 198 
Executive Committee (alspac-exec@bristol.ac.uk). 199 
 200 
RESULTS 201 
The lipidomic dataset that was used to investigate potential biomarkers of PE in children aged 202 
12 years who reported PEs at the age of 18, included 61 PCs and 11 LPCs. The focus on PCs 203 
and LPCs was due to the previous results showing a potential lipidomic signature of PD with 204 
elevated levels of PCs and LPCs (22). The proteomic dataset that we assessed contained 22 205 
members of the coagulation pathway (Supplementary Table 1) as defined by KEGG pathway 206 
analysis (http://www.genome.jp/kegg/pathway.html). 207 
There were no significant differences between the control group and the PE group in terms of 208 
gender, BMI or social class (data not shown). As expected, there was an excess of depression 209 
cases among those with PEs compared to controls with 9 subjects in the PE group reaching 210 
criteria for depression and no cases in the normal control group. Variance in the lipids 211 
profiles of individuals was first explored using PCA. No grouping could be observed through 212 
PCA when examining factors such as PE, gender and BMI. 213 
Early PE signatures at age 12 214 
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Univariate analysis revealed that a total of 34 molecular lipids and 3 coagulation proteins 215 
(PLG, F11, SERPINF2) were different between PE and healthy controls at the nominal P < 216 
0.05 level (Table 2). After FDR correction, sixteen lipids and one protein (plasminogen, 217 
PLG) remained significantly increased. For multivariate analysis, PLS-DA entailed a 218 
resulting model (R2Y = 0.3) with a permutation test P < 0.05. Interestingly, there is a strong 219 
agreement between uni- and multivariate analyses performed individually, in which lowest P-220 
values matching the highest loading scores, and thus, lowest loading rank. Significant 221 
changes of PCs and LPCs with P-value and loading rank corresponding to uni- and 222 
multivariate, respectively, are also presented in Table 2. 223 
Lipidomics and proteomics integration 224 
The coagulation and complement pathway proteins are closely functionally related. For this 225 
reason, we included in our integrative analysis of lipids and proteins the levels of 226 
complement proteins in the total dataset for which there was data available (42). The rCCA 227 
revealed that 17 lipids have a positive correlation with 6 proteins (PLG, HC2, C2, CFH, CLU 228 
and VTN), which exceeded a similarity score higher than 0.3. A strong positive relationship 229 
with the 16 lipids was observed for coagulation proteins plasminogen (PLG), heparin 230 
cofactor 2 (HC2) and the complement pathway protein vitronectin (VTN) (Figure 2). A 231 
relevance network graph illustrates other minor connections observed for complement 232 
proteins clusterin (CLU), C2 and factor H (CFH) (Figure 3). Interestingly, plasminogen had 233 
the highest number of connections, followed by vitronectin and heparin cofactor 2. Table 3 234 
shows specific lipids connections with plasminogen with ten lipids showing a correlation 235 
exceeding a similarity score higher than 0.3. 236 
Underlying clustering in the data  237 
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To detect potential underlying metabolic phenotypes, present in the study population, the 238 
KODAMA algorithm was applied to all individuals with available clinical data (n = 90). 239 
Following this, PAM clustering was performed on KODAMA scores to identify underlying 240 
similar phenotypes in this study population. According to the highest silhouette median value 241 
(Supplementary Figure 1), four different clusters were identified (Figure 1), named A, B, C 242 
and D. Interestingly, PE occurrence was significantly different among clusters (P = 0.007). 243 
Furthermore, neither the BMI nor gender were statistically significant across the clusters 244 
(Table 4). Likewise, depression status and social class were not significantly different across 245 
the clusters (P > 0.05 in both variables, data not shown). Further examination of the clusters 246 
revealed that cluster D exhibited a high probability of developing PE. This cluster exhibited a 247 
PE occurrence of 71%, while clusters A, B and C showed a PE occurrence of 42%, 29% and 248 
19%, respectively.  249 
Clusters were then examined for associations between the cholesterol data with the resulting 250 
KODAMA scores. In total, nine cholesterol parameters (different parameters related to LDL, 251 
VLDL and IDL with specific particle sizes) were significantly associated with the clustering 252 
(Supplementary Table 3). Similarly, KODAMA score plots were performed (Figure 2) 253 
colored by the resulted clusters, PE occurrence, gender and BMI. Score plots color-coded by 254 
the concentration of small LDL particles and the phospholipids to total lipids ratio in small 255 
LDL particles were also performed for visualization and interpretation purposes. There was a 256 
significant difference in distribution of PE cases across the clusters (Figure 2B). Interestingly, 257 
the levels of certain lipoproteins across the clusters were also statistically different 258 
(Supplementary Table 3). Of particular note was differences in the small LDL particles and 259 
phospholipid to total lipid ratio in small LDL particles (Supplementary Figure 3), with a 260 
similar distribution than PE cases. Additional cholesterol-related parameters are shown in 261 
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Supplementary Figure 4. In summary, cluster D representing a metabolic phenotype with a 262 
high probability of developing PE.  263 
 264 
DISCUSSION 265 
The present findings point to early dysregulation of the both lipidome and proteome several 266 
years prior to the development of PEs. Our findings are relevant to PD, anxiety disorder and 267 
depression as approximately 20-30% of subjects who experience PEs go on to develop PD 268 
(53), with approximately 50-60% going on to develop other psychiatric comorbid disorders 269 
(2).  The present findings supports the literature that phospholipid metabolism and the 270 
proteins of the coagulation cascade are abnormal in schizophrenia and depression (26, 54–56) 271 
and extend this literature by providing evidence for such alterations in early childhood before 272 
the development of PEs. Furthermore, the present findings are broadly in line with our 273 
findings from the previous discovery metabolomics, lipidomic and proteomic study in the 274 
ALSPAC cohort where we demonstrated similar changes at age 12 for subjects who later go 275 
on to develop PD (22). The findings have the potential to contribute to risk calculators for 276 
future psychotic illness and mental disorders (4, 57, 58) as well as contributing to an 277 
increased understanding of psychosis and psychiatric illness as a multisystem disorder 278 
involving lipids and proteins (22, 23, 29). Critically, a novelty of our study lies in the 279 
integration of proteomic and lipidomic data, specifically of the lipids PCs and LPCs and the 280 
protein members of the complement and the coagulations cascades from the same subjects. In 281 
so doing we have identified a robust yet unexpected interdependence of these biological 282 
processes which underpin psychotic disease. A tangible advance derived is that our findings 283 
highlight early lipid and protein changes associated with vulnerability to a broad range of 284 
psychiatric disorders and in so doing identify potential novel therapeutic targets.   285 
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There is no simple interpretation of the findings of early LPC and PC changes in relation to 286 
later psychiatric diseases. However, it is noteworthy that several lines of evidence implicate 287 
altered LPC and PC levels in early life and medical morbidities in later life (59). Firstly, 288 
Hellmuth and colleagues observed a positive correlation between LPCs in cord blood during 289 
pregnancy and early weight gain and later life BMI (60). Secondly, Rzehak and colleagues 290 
showed that LPC(14: 0) and PC(38:3) measured at age 6 months positively correlated with 291 
overweight/obesity at 6 years of age. Similar to our findings these observations suggest an 292 
early metabolic alteration that can trigger later disorder (61). Thirdly, a cross-sectional study 293 
of early life suggested an inverse association between obesity and LPC(18:1), LPC(18:2) and 294 
LPC(20:4) in obese individuals between 6 and 15 years of age (62). These LPCs were also 295 
found at lower levels in obese children aged between 7 and 15 years of age in another cross-296 
sectional study (63). Fourthly, an investigation of adults samples from the Western Australian 297 
Pregnancy Cohort showed decreased LPC(18:2) and LPC(18:1) levels in  obese subjects 298 
compared with normal-weight individuals independent of LDL and HDL cholesterol levels, 299 
while LPC(14:0) and PC(32:2) were positively correlated to homeostasis model assessment 300 
(HOMA-IR), as a measure of insulin resistance, in the same study (64). Overall, these studies 301 
suggest elevation of certain LPCs preceding later metabolic and psychiatric disorder.  302 
Perry and colleagues recently showed an association between insulin resistance at age 9 and 303 
PEs at age 18 in the ALSPAC birth cohort (29). Insulin resistance was also associated with 304 
inflammation markers suggesting that inflammation and metabolic risk factors interact to 305 
increase risk of psychosis in some people (29). In relation to this, although opposite effects 306 
have also been reported (65, 66), reduced levels of specific LPCs have been connected with 307 
insulin resistance (45), impaired glucose tolerance (67) and progression to diabetes (68). 308 
Furthermore, schizophrenia has been associated with a high prevalence of other comorbid 309 
disorders such as diabetes (69), metabolic syndrome (70) and cardiovascular disease (71). 310 
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Therefore, the early biomarkers such as LPC(18:2), PC(34:2) and PC(32:1) found in the 311 
present study may reflect a shared vulnerability to both psychosis and cardiometabolic 312 
disorders (59, 68, 72). Previous lipidomic studies in psychosis have identified elevated 313 
plasma levels of LPC(16:0), LPC(18:0), LPC(18:1) and LPC(18:2) in first-episode 314 
neuroleptic drug naïve schizophrenia patients as compared to healthy controls (73). However, 315 
there are inconsistencies in the reported literature, with one study reporting diminished levels 316 
of LPCs in the serum of schizophrenia patients compared to their co-twins as well as healthy 317 
controls (16).  318 
Both the coagulation and the complement pathways have recently been highlighted in 319 
schizophrenia (58, 74, 75). Our current study used the semi-targeted proteomic method of 320 
DIA, to extend these findings and show that upregulation of plasminogen within the 321 
coagulation pathway at age 12 is associated with later PEs. This more complete analysis of 322 
the coagulation pathway proteins in PE was then combined with complement pathway protein 323 
data already available to us on the same subjects (42) to allow a unique integration of 324 
lipidomic, complement and coagulation data. Our integrative network analysis demonstrates 325 
that plasminogen had the strongest connections to PCs and LPCs that were increased in the 326 
PE group. The role of plasminogen as a carrier for PCs and LPCs was previously investigated 327 
by Edelstein and colleagues who suggested that oxidized PCs are integral components of 328 
circulating plasminogen (76), and Leibundgut and coworkers showed that plasminogen 329 
covalently binds oxidized phospholipids that influence fibrinolysis (77) which has known 330 
roles associated with neuroinflammation and neurodegeneration (78). Therefore, increased 331 
plasminogen such as we described in PE is very consistent with higher specific PCs and 332 
LPCs concentrations in PE group. Our findings of elevated levels of plasminogen in subjects 333 
who later report PEs are intriguing in light of recent evidence that blood derived plasminogen 334 
drives brain inflammation (79) and evidence that SERPIN F2, which is the main inhibitor of 335 
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plasminogen-derived plasmin, is upregulated in schizophrenia (80). Interestingly, proteomics 336 
studies discovered a high number of complement and coagulation proteins as lipoprotein-337 
associated components, such as C4A, C4B, VTN, CLU, CFH, SERPINF1/2, KNG, among 338 
others (81). There is a surprisingly strong overlap with the proteins that correlate with 339 
phospholipids in this study and being upregulated in schizophrenia (11)). Together, the data 340 
provides a link between phospholipid binding proteins, (apo)lipoproteins, complement and 341 
coagulation, and a support growing literature implicating these processes in 342 
neuroinflammation and neurodegeneration (78, 82). 343 
Schizophrenia may represent an etiologically heterogeneous disorder with some subjects 344 
having a largely inflammatory basis or an autoimmune etiology (23, 83, 84). Similarly, it is 345 
appreciated that there are heterogeneous outcomes among subjects who experience PEs (2). 346 
This may have relevance to the results of KODAMA (36) analysis in which we identified 347 
four main clusters, of which cluster D was associated with a high probability of subjects 348 
within that cluster experiencing PEs. Interestingly, several the lipoprotein particle size 349 
parameters were also significantly different across the clusters with cluster D having 350 
increased levels of small LDL particles. Smaller LDL particles are more susceptible to 351 
oxidation than larger particles, being more frequently associated to metabolic diseases (85–352 
87). However, in the present study, the oxidation status and lipidomic analyses on specific 353 
LDL particle size were not included at the age of 12, and thus, the results should be 354 
interpreted with caution. Future studies evaluating different LDL subtypes might clarify these 355 
observed associations. 356 
The present study has several strengths: the longitudinal ALSPAC cohort was used and 357 
included both longitudinal clinical assessments and biosampling. The use of samples prior to 358 
disease onset rules out the potential confounding from medications. Furthermore, in contrast 359 
to most other studies our study focused on children who were well at the time of biosampling, 360 
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unlike other studies, where the subjects already had experienced a first episode of psychosis. 361 
The multi-omics integration has allowed a unique insight into the existence of a functional 362 
relationship between these lipids and proteins that was unknown previously in the context of 363 
psychosis. Future work may look at the broader relationship between proteome and lipidome 364 
beyond those specific compounds that we described as discriminant for PE prediction in this 365 
study. A number of limitations should also be acknowledged.  Firstly, the lack of validation 366 
in a similar cohort of subjects with PEs is a limitation. Secondly, while depletion of high 367 
abundance proteins did not impact plasminogen, three of the 22 proteins had been depleted, 368 
so they were interpreted with caution. We did not co-vary for depression, as depression can 369 
be considered a transdiagnostic co-morbidity, and thus our findings are not necessarily 370 
specific to PE.  This is reasonable as PEs are accepted to represent a vulnerability to a broad 371 
range of psychiatric illnesses (2). 372 
 373 
CONCLUSION 374 
Our study provides evidence for protein and lipid signatures at age 12 in subjects who are 375 
apparently well but who report PEs at age 18. These changes are not necessarily specific to 376 
PE, as overlapping changes have been observed previously at age 12 in subjects who later 377 
develop PD (22), and are also observed in association with pre-diabetes, obesity and prior to 378 
other cardio-metabolic disorders (62, 64, 71) suggesting that these disorders share aspects of 379 
their developmental origins. Although there are inconsistences in the literature in terms of 380 
metabolic disorders and schizophrenia (24, 88), the present study strongly suggests that there 381 
is early vulnerability to the development of psychotic experiences and that this involves 382 
molecular interconnections between the lipidome and the proteome.  383 
 384 
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Table 1. Descriptive data of the ALSPAC individuals included in the study. 671 
 
Cases Controls P 
Participants, n 48 67  
Gender 22M, 26F 39M, 28F 0.19 
BMI 18.16 ± 2.85 17.73 ± 2.53 0.40 
Abbreviations: BMI, body mass index. Descriptive information was compared between cases 672 
and controls. Statistical comparisons are from Pearson chi-square or Student’s t-test as 673 
appropriate. For gender: F, female; M, male. BMI expressed as Mean ± SD.  674 
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Table 2. Differential plasma lipids and proteins between PE and control groups. 675 
Compound control Test P FDR LR 
Lipids      
PC(34:1) 2571.91 3013.09 0.0002 0.0066 1 
PC(34:2)* 3759.47 4303.88 0.0002 0.0066 2 
PC(32:1) 238.88 319.25 0.0011 0.0161 3 
PC(36:4)* 135.46 160.55 0.0023 0.0241 4 
PC(36:2) 2940.24 3421.47 0.0003 0.0067 5 
LPC(16:1) 38.27 41.69 0.0080 0.0361 6 
LPC(18:1)* 231.84 273.67 0.0029 0.0259 7 
LPC(20:3)* 37.21 41.58 0.0050 0.0259 8 
PC(36:1) 721.67 945.44 0.0008 0.0137 10 
LPC(18:2)* 394.75 486.68 0.0045 0.0259 11 
PC(38:2) 70.50 86.11 0.0023 0.0241 12 
PC(O-38:6) 28.13 33.58 0.0037 0.0259 14 
PC(38:3) 616.10 752.18 0.0079 0.0361 15 
PC(30:0) 56.88 73.01 0.0098 0.0414 16 
PC(32:0) 175.510 204.390 0.0041 0.0259 17 
PC(36:3) 1753.260 2059.530 0.0049 0.0259 23 
Proteins      
PLG# 843597014.93 1052478260.87 0.0006 0.0138 - 
F11 16925970.15 19053478.26 0.0304 0.2379 - 
SERPINF2 487134328.36 542565217.39 0.0324 0.2379 - 
Abbreviations: F11, coagulation factor XI; FDR, false discovery rate; LPC, 676 
lysophosphatidylcholine; LR, Loading rank; PC, phosphatidylcholine; PE, psychotic 677 
experiences; PLG, plasminogen; SERPINF2, Alpha-2-antiplasmin. P Value of Mann–678 
Whitney U test and loading rank of double cross-validation PLS DA are shown. *Increased 679 
compounds in agreement with O’Gorman et al. including PD individuals (22). #Increased 680 
compounds in agreement with English et al. including PD individuals (23).   681 
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Table 3. Significant lipids correlated with plasminogen from multi and univariate approaches 682 
on PE dataset. 683 
Lipids rCCA Spearman P value 
PC(30:0)* 0.38 0.27 0.005 
PC(32:0)* 0.26 0.19 0.043 
PC(34:1)* 0.24 0.26 0.006 
PC(40:6) 0.29 0.19 0.047 
PC(32:1)* 0.33 0.28 0.003 
PC(38:2)* 0.31 0.20 0.039 
PC(38:3)* 0.35 0.22 0.019 
PC(36:1)* 0.32 0.22 0.022 
PC(35:1) 0.39 0.25 0.007 
PC(36:4)* 0.28 0.23 0.014 
LPC(16:1)* 0.31 0.24 0.010 
PC(40:5) 0.35 0.27 0.004 
PC(40:4) 0.35 0.26 0.006 
PC(33:1) 0.40 0.34 0.001 
PC(37:4) 0.24 0.20 0.032 
PC(36:3)* 0.22 0.19 0.043 
PC(O-36:3) 0.31 0.24 0.013 
PC(31:0) 0.28 0.21 0.029 
Abbreviations: LPC, lysophosphatidylcholine; PC, phosphatidylcholine; PE, psychotic 684 
experiences. P-value of Spearman correlation analysis are shown. Results are listed for the 18 685 
significant compounds using a P-value < 0.05. *Significant lipids associated with PE 686 
development in the present study.  687 
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Table 4. Descriptive data of the ALSPAC individuals by clusters. 688 
 
Cluster A Cluster B Cluster C Cluster D P 
PE 14+, 19- 4+, 10- 5+, 21- 12+, 5- 0.007 
Gender 17M, 16F 8M, 6F 13M, 13F 11M, 6F 0.781 
BMI 17.43 ± 2.29 17.95 ± 3.51 18.88 ± 2.68 17.33 ± 2.72 0.170 
Abbreviations: BMI, body mass index; PE, psychotic experiences. For PE: +, cases; -, 689 
controls. For gender: F, female; M, male. Descriptive information was compared between 690 
clusters. Statistical comparisons are from Pearson chi-square or Student’s t-test as 691 
appropriate. BMI expressed as Mean ± SD.   692 
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 Figure 1. PAM-analysis of the KODAMA output: (A) silhouette plot of PAM including the 693 
optimal number of clusters (j), individuals at each cluster (nj) and the average silhouette 694 
width by samples (avei∊Cj Si); (B) clustering according to the calculated silhouette mean 695 
values.  696 
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 Figure 2. Heat map analysis performed by using regularized canonical correlations analysis 697 
showing the relation between proteomic and lipidomic datasets. For proteomic data, the gene 698 
names are displayed. Correlation strengths are indicated by the color key.   699 
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Figure 3. Relevance network graph depicting correlations derived from rCCA between lipids 700 
and proteins based on a similarity score > 0.3 (45). Nodes (circles) represent variables and are 701 
sized according to number of connections. Lines are colored according to association score 702 
with augmented intensity indicating higher correlation scores.  703 
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Integrated Lipidomics and Proteomics Point to Early Blood-based Changes 
in Childhood Preceding Later Development of Psychotic Experiences: 
Evidence From the Avon Longitudinal Study of Parents and Children 
 
Supplemental Information 
 
Lipidomic Analysis and Data Preprocessing 
Lipidomic data were firstly processed using MZmine 2 (1), then normalized by lipid-class 
specific internal standards, and quantified using the inverse-weighted linear model. Signals of 
internal standards were identified from the standards runs. The internal MS library of retention 
times was adapted to the study by means of a linear correction based on the observed retention 
times in the standards runs using the open source R software (2). 
The dataset was filtered, allowing the signal to be missing in a maximum of 50 % of the samples 
at each of the eight batches. Missing values that remained were then imputed with feature-wise 
half-the-minimum. All lipids that were present in more than 75% of samples were considered 
for statistical analyses.   
 
High-Abundance Protein Depletion of Human Plasma Samples 
To improve the dynamic range for proteomic analysis, 40µl of plasma from each case was 
immunodepleted for removal of the 14 most abundant proteins (Alpha-1-antitrypsin, A1-acid 
glycoprotein, Serum Albumin, Alpha2-macroglobulin, Apolipoprotein A-I, Apolipoprotein A-
II, Complement C3, Fibrinogen alpha/beta/gamma, Haptoglobin, IgG A, IgG G, IgG M, 
Transthyretin, and Serotransferrin) using the Agilent Hu14 Affinity Removal System (MARS) 
coupled to a High Performance Liquid Chromatography (HPLC, Shimadzu LC-10AT) system 
(3). Protein depletion was undertaken according to the manufacturer’s instructions and buffer 
exchange was performed with 50mM ammonium bicarbonate using spin columns with a 
10kDA-molecular weight cut-off (Merck Millipore). Prior to sample preparation for mass 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
Madrid-Gambin et al.  Supplement 
2 
spectrometry, the protein concentration was determined using a Bradford Assay (4), according 
to the manufacturer’s (BioRad) instructions. 
 
Sample Preparation for Mass Spectrometry  
Protein digestion and peptide purification was performed as previously described (5). For 
quality control (QC), an equal aliquot from each protein digest in the experiment was pooled 
into one sample for use as an internal QC. This QC standard was injected at the beginning of 
the MS study to condition the column, and after every ten injections throughout the experiment 
to monitor the MS performance. To facilitate iRT calculation in SkylineTM for DIA data, 
protein digests were spiked with the PierceTM Peptide Retention Time Calibration Mixture (4 
fmol/μl), according to the manufacturers’ instructions. 
 
Targeted Confirmation of Protein Biomarkers Using Data Independent Acquisition (DIA)  
The DIA isolation scheme and multiplexing strategy was based on that from Egertson et al. 
(2013) in which five 4-m/z isolation windows are analysed per scan (6, 7). DIA overcomes 
many of the limitations of untargeted proteomics, for example missing values (8, 9). Samples 
were run on the Thermo Scientific Q Exactive mass spectrometer in DIA mode. Each DIA 
cycle contained one full MS–SIM scan and 20 DIA scans covering a mass range of 490–910Th 
with the following settings: the SIM full scan resolution was 35,000; AGC 1e6; Max IT 55ms; 
profile mode; DIA scans were set at a resolution of 17,000; AGC target 1e5; Max IT 20ms; 
loop count 10; MSX count 5; 4.0 m/z isolation windows; centroid mode (6). The cycle time 
was 2s, which resulted in at least ten scans across the precursor peak. For DIA library 
generation, QC samples were injected in DDA mode (10) at the beginning of the run, and after 
every ten injections throughout the run. The relative fragment-ion intensities, peptide-precursor 
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isotope peaks and retention time of the extracted ion chromatograms from the DIA files were 
used to confirm the identity of the target molecular species (6, 7). 
 
Preprocessing 
For DDA, Label-Free Quantification (LFQ), the human FASTA sequence database was 
searched with MaxQuant (v1.5.2.8) (11, 12), as described (5). False Discovery rates (FDR’s) 
were set to 1% at the peptide and protein level, and only proteins with at least two peptides 
(one uniquely assignable to the protein) were considered as reliably identified. LFQ intensity 
values were used for protein quantification between groups. Only proteins present in >80% of 
samples in at least one group were taken forward for quantification, and the filtered data was 
normalised by subtracting the median intensity for each protein.  
All DIA data was processed in the open-source Skyline software tool (open-source Skyline 
software tool (https://skyline.gs.washington.edu)). This tool provided the interface for visual 
confirmation of protein biomarkers in the samples profiled, without any file conversion. The 
library was constructed by searching the QC injections, which were interspersed after every 
ten injections throughout the run, in MaxQuant. As detailed in the online tutorials and 
publications by the Skyline team, the msms.txt file resulting from the MaxQuant search was 
used to build the library in Skyline. For our peptide targets, mass chromatograms were 
extracted for +2 and +3 precursor charge states and their associated fragment ions. Based on 
our discovery results, we targeted 22 coagulation proteins according to the detailed protocol of 
Egertson (7). For our dataset, the m/z tolerance was < 10 ppm and the average retention time 
window was 2 minutes.  All parent and fragment level data was visually confirmed across the 
samples run, and peak editing was undertaken where necessary, using the peptide Retention 
Time (RT), dotproduct (idop), mass accuracy (< 10 ppm), and a confirmed library match to 
reliably identify and quantify peptides across the DIA runs. For statistical analysis, peak areas 
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of the fragment level data was filtered from the Skyline document grid for analysis in mapDIA, 
an open source bioinformatics tool for pre-processing and  quantitative analysis of DIA data 
(13). Total Ion Sum (TIS) intensity normalisation procedure was applied, followed by peptide 
fragment selection using two standard deviation threshold for outlier detection, in the 
independent sample setup. 
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Supplementary Table S1. Coagulation pathway protein names targeted in this study. 
Protein names Gene names Protein 
Plasminogen PLG P00747 
Antithrombin-III SERPINC1 P01008 
Coagulation factor XI F11 P03951 
Heparin cofactor 2 SERPIND1 P05546 
Coagulation factor XIII B chain F13B P05160 
Coagulation factor IX F9 P00740 
Alpha-2-antiplasmin SERPINF2 P08697 
Kininogen-1 KNG1 P01042 
Vitamin D-binding protein GC P02774 
Alpha-2-macroglobulin A2M P01023 
Carboxypeptidase B2 CPB2 Q96IY4 
Fibrinogen alpha chain FGA P02671 
Plasma serine protease inhibitor SERPINA5 P05154 
Endothelial protein C receptor PROCR Q9UNN8 
Coagulation factor VII F7 P08709 
Coagulation factor XIII A chain F13A1 P00488 
von Willebrand factor VWF P04275 
Coagulation factor V F5 P12259 
Prothrombin F2 P00734 
Coagulation factor XII F12 P00748 
Alpha-1-antitrypsin SERPINA1 P01009 
Coagulation factor X F10 P00742 
Defined by KEGG pathway analysis (http://www.genome.jp/kegg/pathway.html). 
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Supplementary Table S2. Differential plasma PCs and LPCs between the clusters detected. 
Lipid P Value FDR LSD Posthoc 
LPC(16:0) 7.88E-12 1.45E-11 A - B; D - A; C - B; D - B; D - C 
LPC(16:0e) 1.09E-02 1.17E-02 D - A; D - B 
LPC(16:0p) 4.37E-02 4.56E-02 D - A; D - B 
LPC(16:1) 2.06E-10 3.45E-10 A - B; D - A; C - B; D - B; D - C 
LPC(18:0) 3.29E-13 6.96E-13 A - B; D - A; C - B; D - B; D - C 
LPC(18:1)* 3.99E-12 7.76E-12 A - B; A - C; D - A; C - B; D - B; D - C 
LPC(18:2)* 1.80E-08 2.35E-08 A - B; A - C; D - A; D - B; D - C 
LPC(20:3)* 4.41E-09 6.34E-09 A - B; A - C; D - A; D - B; D - C 
LPC(20:4) 1.08E-08 1.46E-08 A - B; A - C; D - A; C - B; D - B; D - C 
LPC(22:5) 2.38E-02 2.52E-02 D - B; D - C 
LPC(22:6) 1.34E-05 1.58E-05 A - B; A - C; D - B; D - C 
PC(16:0e/18:1(9Z)) 4.87E-23 1.17E-21 A - B; A - C; D - A; C - B; D - B; D - C 
PC(30:0) 6.67E-15 1.78E-14 A - B; A - C; D - A; C - B; D - B; D - C 
PC(31:0) 4.06E-06 4.96E-06 A - B; D - A; C - B; D - B; D - C 
PC(32:0) 1.79E-17 8.58E-17 A - B; A - C; D - A; C - B; D - B; D - C 
PC(32:1) 1.04E-09 1.56E-09 A - B; A - C; D - A; C - B; D - B; D - C 
PC(32:2) 3.93E-15 1.13E-14 A - B; D - A; C - B; D - B; D - C 
PC(33:1) 1.44E-11 2.53E-11 A - B; A - C; D - A; C - B; D - B; D - C 
PC(34:1) 1.06E-11 1.90E-11 A - B; A - C; D - A; C - B; D - B; D - C 
PC(34:2)* 9.09E-10 1.39E-09 A - B; A - C; D - A; C - B; D - B; D - C 
PC(35:1) 9.06E-19 5.02E-18 A - B; A - C; D - A; C - B; D - B; D - C 
PC(35:2) 1.29E-14 3.32E-14 A - B; D - A; C - B; D - B; D - C 
PC(35:3) 3.02E-12 6.04E-12 A - B; D - A; C - B; D - B; D - C 
PC(35:4) 8.15E-10 1.28E-09 A - B; D - A; C - B; D - B; D - C 
PC(36:1) 5.71E-18 2.93E-17 A - B; A - C; D - A; C - B; D - B; D - C 
PC(36:2) 4.73E-16 1.70E-15 A - B; A - C; D - A; C - B; D - B; D - C 
PC(36:2) 3.23E-16 1.23E-15 A - B; D - A; C - B; D - B; D - C 
PC(36:4)* 8.19E-19 4.91E-18 A - B; A - C; D - A; C - B; D - B; D - C 
PC(36:5) 1.02E-08 1.41E-08 A - B; D - A; C - B; D - B; D - C 
PC(37:2) 1.48E-20 1.52E-19 A - B; A - C; D - A; C - B; D - B; D - C 
PC(37:3) 1.31E-04 1.48E-04 D - A; D - B; D - C 
PC(37:4) 5.73E-05 6.55E-05 A - B; A - C; D - B; D - C 
PC(38:2) 2.90E-19 1.90E-18 A - B; A - C; D - A; C - B; D - B; D - C 
PC(38:3) 6.42E-15 1.78E-14 A - B; A - C; D - A; C - B; D - B; D - C 
PC(38:4) 2.07E-08 2.66E-08 A - B; A - C; D - A; D - B; D - C 
PC(38:5) 2.11E-15 6.63E-15 A - B; A - C; D - A; C - B; D - B; D - C 
PC(38:6) 2.12E-15 6.63E-15 A - B; A - C; D - A; C - B; D - B; D - C 
PC(39:6) 1.36E-05 1.58E-05 A - B; D - A; C - B; D - B; D - C 
PC(40:4) 1.98E-16 7.92E-16 A - B; A - C; D - A; C - B; D - B; D - C 
PC(40:5) 2.88E-14 7.15E-14 A - B; A - C; D - A; C - B; D - B; D - C 
PC(40:5) 5.39E-08 6.81E-08 A - B; A - C; C - B; D - B; D - C 
PC(40:6) 1.60E-13 3.60E-13 A - B; A - C; D - A; C - B; D - B; D - C 
PC(40:7) 1.45E-19 1.04E-18 A - B; A - C; D - A; C - B; D - B; D - C 
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Lipid P Value FDR LSD Posthoc 
PC(40:8) 2.25E-10 3.69E-10 A - B; A - C; D - A; C - B; D - B; D - C 
PC(O-22:2/22:3) 2.49E-12 5.13E-12 A - B; A - C; D - A; C - B; D - B; D - C 
PC(O-32:1) 2.89E-21 4.16E-20 A - B; A - C; D - A; C - B; D - B; D - C 
PC(O-32:0) 1.44E-25 1.04E-23 A - B; A - C; D - A; C - B; D - B; D - C 
PC(O-34:2) 2.00E-15 6.63E-15 A - B; A - C; D - A; C - B; D - B; D - C 
PC(O-34:3) 2.20E-13 4.80E-13 A - B; A - C; D - A; C - B; D - B; D - C 
PC(O-36:2) 1.19E-13 2.76E-13 A - B; A - C; D - A; C - B; D - B; D - C 
PC(O-36:3) 2.03E-20 1.83E-19 A - B; A - C; D - A; C - B; D - B; D - C 
PC(O-36:4) 3.96E-20 3.17E-19 A - B; A - C; D - A; C - B; D - B; D - C 
PC(O-36:5) 1.08E-20 1.30E-19 A - B; A - C; D - A; C - B; D - B; D - C 
PC(O-38:4) 5.68E-09 8.02E-09 A - B; A - C; D - A; C - B; D - B; D - C 
PC(O-38:5) 2.40E-15 7.20E-15 A - B; A - C; D - A; C - B; D - B; D - C 
PC(O-38:5) 7.81E-12 1.45E-11 A - B; D - A; C - B; D - B; D - C 
PC(O-38:6) 1.43E-08 1.91E-08 A - B; A - C; D - B; D - C 
PC(O-40:5) 5.96E-10 9.53E-10 A - B; A - C; C - B; D - B; D - C 
PC(O-40:6) 3.46E-23 1.17E-21 A - B; A - C; D - A; C - B; D - B; D - C 
PC(O-42:3) 3.22E-09 4.73E-09 A - B; A - C; D - A; C - B; D - B; D - C 
PC(P-18:0/22:6) 1.30E-07 1.62E-07 A - B; A - C; D - A; C - B; D - B; D - C 
PC(P-20:0/22:4) 5.27E-17 2.37E-16 A - B; A - C; D - A; C - B; D - B; D - C 
Abbreviations: FDR, false discovery rate; LPC, lysophosphatidylcholine; PC, 
phosphatidylcholine. P Value of one-way analysis of variance (ANOVA). Fisher’s Least 
Significant Difference (LSD) method was used as posthoc. Results are listed for the 17 
significant compounds. *Increased compounds in agreement with O’Gorman et al. that 
included PD individuals (14). 
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Supplementary Table S3. Association of KODAMA models with cholesterol parameters at 
the age of 7. 
 
ALSPAC variable P FDR 
Total cholesterol in medium LDL  <0.001 <0.001 
Concentration of small LDL particles  <0.001 <0.001 
Total lipids in small LDL <0.001 <0.001 
Phospholipids to total lipids ratio in chylomicrons and 
extremely large VLDL 
<0.001 <0.001 
Phospholipids to total lipids ratio in very large VLDL <0.001 <0.001 
Phospholipids in IDL <0.001 <0.001 
Cholesterol esters to total lipids ratio in medium LDL <0.001 <0.001 
Free cholesterol to total lipids ratio in medium LDL <0.001 <0.001 
Phospholipids to total lipids ratio in small LDL <0.001 <0.001 
Abbreviations: IDL, intermediate-density lipoprotein; LDL, low-density lipoprotein; VLDL, 
very low-density lipoprotein. P value of K-test and FDR are shown. Results are classified into 
demographic data and cholesterol profile. After FDR, PE and 9 cholesterol parameters were 
related to clustering (FDR-corrected P-value < 0.001) for 90 individuals with available 
cholesterol data at the age of 7. 
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Supplementary Figure S1.  Average silhouette width by number of clusters based on PAM 
analysis. 
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Supplementary Figure S2.  Box plots of the distribution of significant lipids among clusters 
in the present study that are in agreement with O’Gorman 2017 (14). LPC, 
lysophosphatidylcholine; PC, phosphatidylcholine. Significances of the lipids by clusters are 
shown in Supplementary Table S1. Cluster D and A was composed by 70.6% and 32.6%, 
respectively, of PE cases, while cluster B and C was composed by 28.5% and 19.23%, 
respectively (Chi square p= 0.007). 
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Supplementary Figure S3. Identification of clusters and their relationship with other 
parameters. KODAMA score plot colored by (A) PAM clustering of KODAMA output colored 
by clusters; (B) psychotic experiences (K-test FDR-corrected P-value = 0.012); (C) body mass 
index (FDR-corrected P-value = 0.405); (D) gender (FDR-corrected p-value = 1.000); (E) 
concentration of small LDL particles grouped by quantiles (FDR-corrected P-value < 0.001) 
and (F) phospholipids to total lipids ratio in small LDL particles grouped by quantiles (FDR-
corrected P-value < 0.001).  
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Supplementary Figure S4. KODAMA score plot grouped by quantiles of the significant 
cholesterol parameters from K-test (FDR-corrected p-value < 0.001). CM, chylomicrons; IDL, 
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intermediate density lipoprotein particles; L, large; LDL, low density lipoprotein; PL, 
phospholipids; S, small; VLDL,  very low density lipoprotein; XL, very large; XXL, extremely 
large. 
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